Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2006

View Archived Issues

Preclinical and clinical efficacy and safety of MB-06322 in type 2 diabetes

CHIR-258 continues clinical development

BTG to begin U.S. phase II study for Varisolve

Synthetic Blood International signs Mexican letter of intent for Oxycyte trial

Innate Pharma strengthens TLR platform

Bio-Bridge Science reports preclinical findings from oral HIV vaccine

SPA for registrational metastatic melanoma trial of ipilimumab plus chemotherapy

GTI-2040 to be studied in MDS and AML

Cognate Therapeutics changes name to Cognate BioServices

Phase II study of IR-103 in HIV patients cleared for expansion

PharmaFrontiers changes name to Opexa Therapeutics

Positive results reported for Exubera inhaled insulin

Panflu induces immune response in healthy volunteers

Postoperative MAGE-A3 vaccine well tolerated in NSCLC

Cytokinetics and GSK extend research collaboration

Phase I and II studies evaluate AIR inhaled insulin system

Toray granted Japanese license to AC-200

Neurodex NDA review period extended

Oxybate improves fibromyalgia symptoms

Phase II studies reveal nilotinib activity in hematological malignancies

MT-103 active in non-Hodgkin's lymphoma

Clazosentan reduces occurrence of cerebral vasospasm in study

Avastin approved for second-line use in metastatic colorectal cancer

Cognition improvement by novel alpha7 nAChR partial agonist in rats

Recent Janssen and Zambon patents report novel analgesic agents

Novel agents for treating neurological disorders disclosed in recent patent literature

Novel dopamine D3 receptor antagonists for drug dependence emerge from Bioprojet R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...